Adoptive immunotherapy for Hodgkin's lymphoma

Int J Hematol. 2006 Jun;83(5):385-90. doi: 10.1532/IJH97.06107.


Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies can be achieved. In this article, we discuss the promise of Epstein-Barr virus-specific cytotoxic T-lymphocytes, the roles of cytokines, and other strategies for overcoming the immune-evasion mechanisms in Hodgkin's lymphoma.

Publication types

  • Review

MeSH terms

  • Cytokines / immunology
  • Epstein-Barr Virus Infections / immunology
  • Hodgkin Disease / immunology*
  • Hodgkin Disease / therapy*
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Lymphoma, Non-Hodgkin / immunology
  • Lymphoma, Non-Hodgkin / therapy
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / transplantation*
  • Tumor Escape / immunology*


  • Cytokines